OBJECTIVE: Goal of our case control study was to establish the presence of antibodies to glutamic acid decarboxylase (GAD) in patients with chronic psychotic disorders. METHODS: Serum levels of GAD antibodies in 12 patients with chronic psychotic disorders (schizophrenia and schizoaffective disorders) and 10 age-matched healthy control subjects were evaluated utilizing enzyme linked immunosorbitent assay (ELISA). RESULTS: Antibodies to GAD in patients with chronic psychotic disorders have a higher mean than nonpatient control individuals. CONCLUSION: Our findings provide the first in-vivo evidence of positive GAD antibodies in chronic psychotic disorders and potentially may be used as a screening for these disorders.
OBJECTIVE: Goal of our case control study was to establish the presence of antibodies to glutamic acid decarboxylase (GAD) in patients with chronic psychotic disorders. METHODS: Serum levels of GAD antibodies in 12 patients with chronic psychotic disorders (schizophrenia and schizoaffective disorders) and 10 age-matched healthy control subjects were evaluated utilizing enzyme linked immunosorbitent assay (ELISA). RESULTS: Antibodies to GAD in patients with chronic psychotic disorders have a higher mean than nonpatient control individuals. CONCLUSION: Our findings provide the first in-vivo evidence of positive GAD antibodies in chronic psychotic disorders and potentially may be used as a screening for these disorders.
Authors: K McKnight; Y Jiang; Y Hart; A Cavey; S Wroe; M Blank; Y Shoenfeld; A Vincent; J Palace; B Lang Journal: Neurology Date: 2005-12-13 Impact factor: 9.910
Authors: G R Vreugdenhil; N C Schloot; A Hoorens; C Rongen; D G Pipeleers; W J Melchers; B O Roep; J M Galama Journal: Clin Infect Dis Date: 2000-10-25 Impact factor: 9.079
Authors: Takanori Hashimoto; David W Volk; Stephen M Eggan; Karoly Mirnics; Joseph N Pierri; Zhuoxin Sun; Allan R Sampson; David A Lewis Journal: J Neurosci Date: 2003-07-16 Impact factor: 6.167
Authors: Mette Richner; Nelson Ferreira; Anete Dudele; Troels S Jensen; Christian B Vaegter; Nádia P Gonçalves Journal: Front Neurosci Date: 2019-01-14 Impact factor: 4.677